Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 905-908-9 | CAS number: -
Endpoint summary
Administrative data
Description of key information
LD50 for acute oral and dermal toxicity: > 2000 mg/kg bodyweight
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- valid, reliable and conclusive study under GLP.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Valid, reliable and conclusive study under GLP.
Additional information
This valid, reliable and conclusive study was performed to assess the acute oral toxicity of the test item Reaction Mass of CNX1 -55 following a single oral administration in the Wistar strain rat. The testing was performed in accordance with UK GLP standards. The method was designed to be compatible with the OECD Guidelines for the Testing of Chemicals No. 423 "Acute Oral Toxicity - Acute Toxic Class Method" (adopted 17 December 2001) and Method B1 tris Acute Toxicity (Oral) of Commission Regulation (EC) No. 440/2008.
Conclusion: The acute oral median lethal dose (LD50) of the test item Reaction Mass of CNX1-55 in the female Wistar strain rat was estimated to be greater than 2000 mg/kg body weight.
Inhalation endpoint
Based on Regulation (EC) No 1907/2006, Annex VIII, column 2, the study on acute toxicity via inhalation routes needs to be conducted if the inhalation for humans via inhalation is likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size. Since the test substance decomposes at 255 °C, no vapour pressure can be determined, and no exposure of humans to vapour is therefore to be expected. Thus, a study on acute toxicity via inhalation routes can be waived, and a study on acute toxicity via inhalation routes needs not to be conducted.
Dermal endpoint
In a reliable, conclusive and valid study, the acute dermal toxicity of the test item Reaction mass of CXN1-55 on the Wistar strain rat was determined according to OECD TG 402, Method B3 (EC) and US EPA, OPPTS 870.1200 under GLP.
Conclusion: The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.
Justification for classification or non-classification
Based on the current data, CNX1 -55 is not classified for acute toxicity according to Regulation (EC) No. 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
